Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free:

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site:, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Google Analytics

Targeted advertising cookies


The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at or by post at:

24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal JPI



Welcome to the OXYGENATE portal!

OXYGENATE "Oxylipins signature to monitor the cardiometabolic status and its response to dietary intervention"

The OXYGENATE project aims to uncover and validate the oxylipin signatures reflecting the trajectory from health to cardiometabolic syndrome and its relationships with diet



The OXYGENATE Project is supported by the EU Joint Programming Initiative A Healthy Diet for a Healthy Life through participating organization's local funding agencies.
oxylipins 2
What are oxylipins?
Oxylipins refers to a superclass of lipid mediators produced from oxygenation of polyunsaturated fatty acids. They include the prostanoids produced by cyclooxygenases; leukotrienes, resolvins, hepoxilins and mid-chain hydroxy-FA generated by lipoxygenases, epoxy-FA and omega-terminal hydroxy-FA produced by several cytochrome P450 monooxygenases as well as iso/neuroprostanes resulting from the free-radical-mediated oxidation of PUFAs.
Cardiometabolic syndrome
The cardiometabolic syndrome is a progressive condition encompassing a constellation of metabolic abnormalities. These include abdominal obesity, insulin-resistant glucose metabolism, dyslipidaemia and increased blood pressure.
These abnormalities are risk factors for cardiometabolic diseases and in particular cardiovascular diseases which represent an enormous burden for health care with a cost for the EU economy estimated at more than €196 billion per year.
heart attack
Rational & Hypothesis
There is an urgent need to find reliable early biomarkers of the cardiometabolic syndrome allowing intervention before irreversible damage develops while assessing the efficacy of nutritional prevention.
Oxylipins are involved in the homeostasis of various process related to the cardiometabolic status and there is a consistent link between diet, oxylipins and cardiometabolic dysregulations
Comprehensive oxylipin profiling could identify reliable early biomarker patterns of the cardiometabolic syndrome and will provide a new tool for assessing the efficacy of dietary interventions.
Using an optimized targeted lipidomic approach and leveraging 2 independent prospective cohorts (i.e. the Polish PURE and the French NutriNet-Santé cohorts) and 2 whole-diet interventions (Shopus and iMAPS) we will identify and validate oxylipin signatures (i) differentiating individuals at different stages of CardMetS and with different dietary patterns and (ii) evolving consistently with dietary interventions affecting the cardiometabolic endpoints.